title: Third-party-mediated graft rejection and graft-versus-host disease after T-cell-depleted bone marrow transplantation, as demonstrated by hypervariable DNA probes and HLA-DR polymorphism.
abstract: Graft rejection after marrow transplantation is generally thought to be mediated by alloreactive immune effector cells of host origin. Transfused blood products also contain immune cells capable of alloreactivity against both donor graft and host. To reduce the risk of transfusion-associated graft-versus-host disease (GVHD) and graft rejection, standard procedure is to irradiate all blood products with at least 1,500 rad before transfusion. We report a patient with chronic myelogenous leukemia who developed graft rejection and GVHD after receiving a T-cell-depleted transplant from a serologically HLA-A, B, DR/DQ matched and mixed lymphocyte culture (MLC) nonreactive unrelated donor. Cytogenetic analysis of marrow cells collected at the time of graft rejection revealed a PH1-negative female karyotype that was not consistent with donor cells. Use of specific minisatellite DNA probes (YNH 24, H-RAS, and 3' HVR) revealed the exclusive presence of third-party (neither donor nor recipient) restriction-fragment-length polymorphisms (RFLP) in both peripheral blood and marrow. Repeat RFLP analysis 3 days later showed persistence of this unique third-party banding pattern. DNA-based HLA-typing, using polymerase chain reaction (PCR) and oligonucleotide probe hybridization, also showed these cells to be derived from an individual whose HLA-DR type was distinct from donor and recipient. Together, these findings suggested the presence of a proliferating population of transfused cells possessing alloreactivity against both donor graft and host, despite prior irradiation of all blood products with 2,000 rad. Limiting dilution analysis to assess the frequency of irradiated lymphocytes able to respond to mitogen revealed an approximate 5- to 6-log reduction at 1,500 to 2,000 rad as compared with unirradiated controls. These data indicate that a small percentage of lymphocytes can survive irradiation at these doses and suggest that existing blood-product irradiation guidelines may require reassessment, especially in T-cell-depleted transplant recipients.
authors.affiliation: Department of Medicine, Medical College of Wisconsin, Milwaukee 53226.
authors.forename: W
authors.initials: W
authors.lastname: Drobyski
authors.forename: S
authors.initials: S
authors.lastname: Thibodeau
authors.forename: R L
authors.initials: RL
authors.lastname: Truitt
authors.forename: L A
authors.initials: LA
authors.lastname: Baxter-Lowe
authors.forename: J
authors.initials: J
authors.lastname: Gorski
authors.forename: R
authors.initials: R
authors.lastname: Jenkins
authors.forename: J
authors.initials: J
authors.lastname: Gottschall
authors.forename: R C
authors.initials: RC
authors.lastname: Ash
mesh_terms: D016026:Bone Marrow Transplantation / Q000276:immunology* / Q000473:pathology; D015343:DNA Probes, HLA; D005260:Female; D006084:Graft Rejection; D006086:Graft vs Host Disease / Q000276:immunology* / Q000473:pathology; D006684:HLA-DR Antigens / Q000235:genetics; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000601:surgery; D015345:Oligonucleotide Probes; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D015343:DNA Probes, HLA; D006684:HLA-DR Antigens; D015345:Oligonucleotide Probes